Cell Therapy News/Articles, page-11493

The FDA have it all under control @eyeswideopen .... oh wait they actually don't - look at all the EUA's issued for COVID-19 and the age 'cut-offs' ... The Remestemcel-L EAP is active for the treatment of MIS-C associated with COVID-19 in children but it gives one the feeling of being a little 'used' by the FDA ?

https://clinicaltrials.gov/ct2/show/NCT04456439?term=Remestemcel-L&draw=3&rank=18

_{Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)}





https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19

_{FDA Approves First Treatment for COVID-19}

Today, the U.S. Food and Drug Administration approved the antiviral drug Veklury (remdesivir) for use in adult and pediatric patients 12 years of age and older and weighing at least 40 kilograms (about 88 pounds) for the treatment of COVID-19 requiring hospitalization. Veklury should only be administered in a hospital or in a healthcare setting capable of providing acute care comparable to inpatient hospital care. Veklury is the first treatment for COVID-19 to receive FDA approval.